A National Formulary for Canada

Aidan Hollis and Stephen Law

Canadian Public Policy, 2004, vol. 30, issue 4, pages 445-452

Abstract: This article analyzes the benefits and costs of replacing Canada's ten different provincial formularies with one single national formulary. The 2002 Romanow Commission on the Future of Health Care in Canada recommended that Canada should have a National Drug Agency which would maintain a national formulary, replacing the existing provincial formularies which balkanize drug markets across Canada. This recommendation has been in part incorporated into the Common Drug Review in which the provinces (excluding Quebec) have agreed to undertake a single evaluation of all new drugs; provinces, however, retain their own formularies and decide which products to list. This balkanized approach to listing and insurance coverage of drugs substantially weakens the bargaining position of the provinces and leads to higher costs.

Date: 2004
View list of references

Downloads: (external link)
http://economics.ca/cgi/jab?journal=cpp&view=v30n4/CPPv30n4p445.pdf Full text (application/pdf)
No access restriction except for the four most recent issues.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: http://EconPapers.repec.org/RePEc:cpp:issued:v:30:y:2004:i:4:p:445-452

Ordering information: This journal article can be ordered from
http://www.utpjournals.com/cpp/

Access Statistics for this article

Canadian Public Policy is edited by James B. Davies

More articles in Canadian Public Policy from University of Toronto Press
Address: University of Toronto Press Journals Division 5201 Dufferin Street Toronto, Ontario, Canada M3H 5T8
Series data maintained by Prof. Werner Antweiler ().